HomeCompareCNCR vs SCHD

CNCR vs SCHD: Dividend Comparison 2026

CNCR yields 22.17% · SCHD yields 3.44%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CNCR wins by $54.4K in total portfolio value
10 years
CNCR
CNCR
● Live price
22.17%
Share price
$9.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$83.4K
Annual income
$8,443.92
Full CNCR calculator →
SCHD
Schwab U.S. Dividend Equity ETF
● Live price
3.44%
Share price
$30.68
Annual div
$1.06
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.0K
Annual income
$422.61
Full SCHD calculator →

Portfolio growth — CNCR vs SCHD

📍 CNCR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCNCRSCHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CNCR + SCHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CNCR pays
SCHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CNCR
Annual income on $10K today (after 15% tax)
$1,884.70/yr
After 10yr DRIP, annual income (after tax)
$7,177.33/yr
SCHD
Annual income on $10K today (after 15% tax)
$292.49/yr
After 10yr DRIP, annual income (after tax)
$359.22/yr
At 15% tax rate, CNCR beats the other by $6,818.11/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CNCR + SCHD for your $10,000?

CNCR: 50%SCHD: 50%
100% SCHD50/50100% CNCR
Portfolio after 10yr
$56.2K
Annual income
$4,433.26/yr
Blended yield
7.89%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CNCR buys
0
SCHD buys
0
No recent congressional trades found for CNCR or SCHD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCNCRSCHD
Forward yield22.17%3.44%
Annual dividend / share$2.00$1.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$83.4K$29.0K
Annual income after 10y$8,443.92$422.61
Total dividends collected$49.9K$3.9K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: CNCR vs SCHD ($10,000, DRIP)

YearCNCR PortfolioCNCR Income/yrSCHD PortfolioSCHD Income/yrGap
1← crossover$12,917$2,217.29$11,224$344.10+$1.7KCNCR
2$16,498$2,676.77$12,567$354.98+$3.9KCNCR
3$20,848$3,195.17$14,038$365.30+$6.8KCNCR
4$26,081$3,773.49$15,648$375.06+$10.4KCNCR
5$32,319$4,411.80$17,410$384.27+$14.9KCNCR
6$39,690$5,109.26$19,335$392.95+$20.4KCNCR
7$48,333$5,864.15$21,437$401.10+$26.9KCNCR
8$58,390$6,673.88$23,733$408.75+$34.7KCNCR
9$70,012$7,535.13$26,237$415.91+$43.8KCNCR
10$83,357$8,443.92$28,968$422.61+$54.4KCNCR

CNCR vs SCHD: Complete Analysis 2026

CNCRStock

The index is composed of the common stock of approximately 30 pharmaceutical or biotechnology companies identified by the fund's index provider, as having a high strategic focus on the development of drugs that harness the body's own immune system to fight cancer. The adviser attempts to invest all, or substantially all, of its assets in the component securities and ADRs that make up the index. At least 80% of its total assets will be invested in the component securities of the index. The fund is non-diversified.

Full CNCR Calculator →

SCHDETF

The fund’s goal is to track as closely as possible, before fees and expenses, the total return of the Dow Jones U.S. Dividend 100 Index.

Full SCHD Calculator →
📬

Get this CNCR vs SCHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CNCR vs JEPICNCR vs OCNCR vs KOCNCR vs MAINCNCR vs VYMCNCR vs DGROCNCR vs VIGCNCR vs HDV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.